eyeWatch vs. Trabeculectomy RCT (evT)

Inclusion Criteria: * Aged between 18 and 95 years, * Diagnosis of primary open-angle glaucoma, pseudo-exfoliative glaucoma or pigmentary glaucoma in the study eye (based on \[1\] glaucomatous optic neuropathy and \[2\] visual field defects in keeping with optic disc appearance), * Phakic or pseudophakic study eye, * Indication for primary filtering surgery (defined as a corrected IOP ≥ 20 mmHg in the study eye, under maximally tolerated therapy on 2 consecutive measurements made on different days prior to surgery), * Undergoing surgery and post-operative follow-up at one of the investigations centres: Montchoisi Clinic, Swiss Visio, Lausanne, Switzerland OR Manchester Royal Eye Hospital, Manchester, United-Kingdom, * Patient agreed to sign the written inform consent prior to entering the study, * Patient is able and willing to complete post-operative follow-up requirements. Exclusion Criteria: * Diagnosis of secondary glaucoma except for pseudo-exfoliative or pigmentary glaucoma (neovascular glaucoma, congenital glaucoma, uveitic glaucoma…), * Previous filtering or tube surgery in the same eye (including trabeculectomy, deep-sclerectomy and all GDDs / excluding XEN gel stents, angle surgery, cataract surgery and all MIGS), * Recent ophthalmic surgery (less than 3 months prior to inclusion) or indication for a combined procedure (no combined surgeries will be performed), * Narrow iridocorneal angles defined as a Shaffer grade ≤ 2 or presence of iris bombé, * Endothelial cell density \< 1500 cells/mm², * Presence of other significant pathologies in the study eye (including extensive conjunctival thinning or scarring, optic neuropathy of non-glaucomatous etiology, retinal vein occlusion, retinal artery occlusion, corneal opacification or irregularities, ocular malformations such as microphthalmia, concurrent inflammation/infection), * Proliferative or severe non-proliferative retinopathy in either eye, * Any sign of past or present uveitis, * Severe systemic disease or disabling conditions (including chronic renal failure, history of organ transplantation), * Current or recent participation in another clinical trial (less than 3 months prior to inclusion), * Pregnancy or breast-feeding, * Inability to give informed consent to participate to a clinical investigation.